Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [4606]

High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer risk

High levels of novel biomarker GDF15 in steatotic liver patients linked to increased liver cancer risk

Getting personal: Accelerating personalised and precision medicine integration into clinical cancer

Getting personal: Accelerating personalised and precision medicine integration into clinical cancer

World-first study into precision medicine for high-risk childhood cancer yields extraordinary results

World-first study into precision medicine for high-risk childhood cancer yields extraordinary results

ASCO 2024: Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-mutated NSCLC

ASCO 2024: Osimertinib poised to change standard of care treatment for patients with locally advanced EGFR-mutated...

Biomarker could improve prediction of response to immunotherapy in black skin cancer

Biomarker could improve prediction of response to immunotherapy in black skin cancer

Researchers develop a nanoparticle that can penetrate the blood-brain barrier

Researchers develop a nanoparticle that can penetrate the blood-brain barrier

Team facilitates personalised treatment opportunities for malignant brain tumour, glioblastoma

Team facilitates personalised treatment opportunities for malignant brain tumour, glioblastoma

Immune cells hunt down cancer around the body – discovery could lead to personalised treatments for advanced breast cancer

Immune cells hunt down cancer around the body – discovery could lead to personalised treatments for advanced...

Phase 2 data for apalutamide plus androgen deprivation therapy following radical prostatectomy in patients with high-risk localised prostate cancer show 100% biochemical free recurrence rate more than two years post-surgery

Phase 2 data for apalutamide plus androgen deprivation therapy following radical prostatectomy in patients with...

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive bladder cancer

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk non-muscle-invasive...

More from ecancer